Abstract
Atrial Fibrillation WO 2016012783, MyoKardia
HEART, MYOCARDIAL INFARCTION, ATRIAL FIBRILLATION, CARDIOVASCULAR DISEASE
The first two authors shared first author.
L.F. and P.K. are listed as inventors on two patents held by University of Birmingham (Atrial Fibrillation Therapy WO 2015140571, Markers for Atrial Fibrillation WO 2016012783). L.F. has received institutional research grants and non-financial support from European Union, DFG, British Heart Foundation, Medical Research Council (UK), NIHR, and several biomedical companies. K.W. reports grants from AFNET, during the conduct of the study; grants from Biotronik; personal fees from Biotronik; and personal fees from Boston Scientific, from Resmed, and from Novartis, outside the submitted work.J.P.P. has consulted for Maze Therapeutics.P.E. has received sponsored research support from Bayer AG, IBM Health, Bristol Meyers Squibb, and Pfizer; he has also served on advisory boards or consulted for Bayer AG, MyoKardia, and Novartis.R.B.S. has received lecture fees and advisory board fees from BMS/Pfizer outside this work.The other authors report no conflicts.A.S. reports grants from AFNET, during the conduct of the study, and grants from BIOTRONIK, outside the submitted work.C.R. is supported by a grant from Bayer AG to the Broad Institute focused on the development of therapeutics for cardiovascular disease.T.Z. is listed as a co-inventor of an international patent on the use of a computing device to estimate the probability of myocardial infarction (International Publication Number WO2022043229A1).